Nabi Biopharmaceuticals (NABI) Reports Q3 Loss of $0.12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts NABI Hot Sheet
Price: $1.80 --0%
Financial Fact:
Basic income (loss) per share: -0.26
Today's EPS Names:
AEHR, VFS, CMTL, More
Financial Fact:
Basic income (loss) per share: -0.26
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nabi Biopharmaceuticals (NASDAQ: NABI) reported Q3 EPS of ($0.12), versus ($0.07) reported last year. Revenue for the quarter came in at $632 thousand, versus $1.1 million reported last year.
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Oaktree exits TORM stake via 6.3 million share secondary offering
- Stifel Reiterates Buy Rating on Sportradar Group AG (SRAD) Amid 2% Drop
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
